

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study

A Johannessen, E R Omenaas, P S Bakke, A Gulsvik



Thorax 2005;60:842-847. doi: 10.1136/thx.2005.043943

Background: The Global Initiative for Obstructive Lung Disease (GOLD) has defined chronic obstructive pulmonary disease (COPD) as a post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity (FEV₁/FVC) of <0.7. In the first general population based study to apply post-bronchodilator values, the prevalence and predictors of GOLD defined COPD were assessed and the implications of β_2 agonist reversibility testing examined.

Methods: Based on a random population sample, 2235 subjects (77%) aged 26-82 years performed spirometric tests before and 15 minutes after inhaling 0.3 mg salbutamol.

Results: The prevalence of GOLD defined COPD was 7.0% (95% confidence interval (CI) 5.9 to 8.0). This estimate was 27% lower than COPD defined without bronchodilatation. One percent of the population had severe or very severe COPD. Compared with women, men had 3.1 (95% CI 2.1 to 4.8) times higher odds for COPD. Subjects with a smoking history of more than 20 pack years had an odds ratio (OR) of 6.2 (95% CI 3.4 to 11.0) for COPD relative to never-smokers, while subjects older than 75 years had an OR of 18.0 (95% CI 9.2 to 35.0) relative to those below 45 years. Subjects with primary education only had an OR of 2.8 (95% CI 1.4 to 5.3) compared with those with university education. Subjects with body mass index (BMI) <20 kg/m² were more likely than subjects with BMI 25-29.9 kg/m² to have COPD (OR 2.4, 95% CI 1.1 to 5.3). The adjusted proportion of COPD attributable to smoking was 68%.

Conclusions: These results indicate that community programmes on prevention of COPD should focus on anti-smoking, nutritional aspects, and socioeconomic conditions. The effect of β_2 reversibility testing on prevalence estimates of COPD was substantial.

See end of article for authors' affiliations

Correspondence to:
Ms A Johannessen,
Institute of Medicine,
University of Bergen, N-
5021 Bergen, Norway;
ane.johannessen@helse-
bergen.no

Received 17 March 2005
Accepted 30 June 2005
Published Online First
5 August 2005

The recent international guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD)^{1,2} have facilitated comparison of study results regarding chronic obstructive pulmonary disease (COPD). The new joint position paper from the European Respiratory Society (ERS) and the American Thoracic Society (ATS)³ has further enhanced this consensus through advocating the same disease definition.

GOLD defines COPD through post-bronchodilatation spirometric testing as a ratio of forced expiratory volume in 1 second (FEV₁) to forced vital capacity (FVC) of <0.7. The use of post-bronchodilator values is essential because of the mainly irreversible airflow limitation that characterises COPD.^{2,4} The prevalence of COPD using pre-bronchodilator values gives an overestimation, especially among young adults.⁴

This is the first study to present the prevalence and predictors of GOLD defined COPD in a general adult population. Although several population based studies claim to present prevalence estimates of COPD according to the GOLD criteria,⁵⁻⁹ none of these has defined COPD with post-bronchodilator spirometric values for adults with a broad age range. The need for, and importance of, correct use of GOLD guidelines with post-bronchodilator values has recently been stressed.^{4,10}

The main objectives of the study were to estimate the prevalence and predictors of GOLD defined COPD in a general adult population. We also wanted to investigate how the bronchodilatation test affected the prevalence estimates, and whether the associations between disease and risk factors remained the same before and after bronchodilatation.

METHODS

Subjects

In 1985 there were 267 403 subjects aged 15-70 years living in Hordaland County, Norway. A random sample (N = 4992) was invited to answer a respiratory health questionnaire; 75% of the participants (N = 3370) lived in Bergen and 11 surrounding municipalities. Of 2912 subjects still living in the study area in 1996-7, 2401 (82%) participated in a follow up study. Acceptable spirometry with reversibility testing was achieved in 2235 (77%, fig 1). The most frequent reason for unsuccessful spirometric testing was unwillingness to inhale a β_2 agonist (3.0%).

Respiratory symptoms (cough, dyspnoea, wheeze) and diseases (asthma, chronic bronchitis, emphysema and COPD), occupational dust or gas exposure, educational level, and smoking habits were registered in self-administered questionnaires.¹¹ Carboxyhaemoglobin (HbCO) was measured for each participant. Almost all current smokers (91%) and only 4% of non-smokers had HbCO >1.7%.

One pack year was defined as 20 cigarettes a day for 1 year. Occupational dust or gas exposure was defined as an affirmative answer to the question "Have you ever had a work place with much dust or gas in the air?" Information on the highest completed educational level was classified into three categories: (1) 9 year compulsory school; (2) continuation school, lower secondary school, upper secondary school, or technical school; (3) college or university.¹² Height and weight were registered and body mass index (BMI) was categorised into four groups: <20 kg/m², 20-24.9 kg/m²,

Abbreviations: BMI, body mass index; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity




Figure 1 Flow chart of sample performing spirometry with reversibility test in the Hordaland County Cohort Study 1996–7.

25–29.9 kg/m², and ≥ 30 kg/m². Residential area was divided into urban (Bergen) and rural (11 surrounding municipalities). Information on BMI, pack years, educational level, and occupational exposure was lacking for 7, 48, 26 and 50 subjects, respectively.

The study was approved by the regional committee of medical research ethics.

Spirometry and reversibility testing

FVC and FEV₁ were measured with Gould 2100 pulmonary function equipment¹³ according to the ATS criteria.^{14, 15} Spirometric tests were performed before and 15 minutes after inhalation of salbutamol powder from a Turbuhaler. Each dose was 0.1 mg, and three inhalations were administered 1–2 minutes apart, giving a total dose of 0.3 mg salbutamol.

We estimated COPD according to the GOLD guidelines as post-bronchodilator FEV₁/FVC of <0.7 .² In order to analyse the effect of reversibility testing on disease definition, we also estimated COPD defined without bronchodilatation. Subjects were grouped into four categories based on their pre- and post-bronchodilator FEV₁/FVC ratio combinations.

Severity of disease was defined by level of FEV₁ as percentage predicted.² Predicted values of FEV₁ were assessed using equations from a Norwegian reference population.¹⁶

Statistical analysis

Analyses were performed with Stata 8.0 and SPSS 12.0 for Windows.^{17, 18} All p values were two sided and values below 0.05 were considered statistically significant if not stated otherwise. Sex, age, BMI, smoking habits, pack years, educational level, occupational exposure, and residential area were analysed as risk factors for COPD. All possible two way interaction effects from the risk factors in relation to post-bronchodilator FEV₁/FVC were examined in logistic regression analyses. The significance level for the interaction effects was set to 0.01. Adjusted odds ratios (OR) and 95% confidence intervals (CI) for each risk factor were estimated in a backwards stepwise logistic regression analysis.

Adjusted attributable fractions with confidence intervals were estimated for smoking and occupational exposure to airborne agents. Attributable fraction was defined as the proportion of prevalence in the total population that could have been avoided if the exposure of interest had been removed.¹⁹ The definition presupposed that all other exposures remained stable.

One way ANOVA with Bonferroni tests was performed for multiple pairwise comparisons for the four combinations of pre- and post-bronchodilatation spirometry results. Mean pre- and post-bronchodilator FEV₁, FVC, and FEV₁/FVC were compared across the four groups.

RESULTS

Characteristics of study population

A similar number of men and women participated in the study (table 1). The mean (SD) age of the study population was 49.8 (14.7) years (range 26–82). Mean (SD) BMI was 25.6 (4.0) kg/m². One third of the participants smoked on a daily basis, while almost 40% were never smokers. Female ever smokers had smoked a mean (SD) of 12 (10) pack years, while male ever smokers had smoked as much as 17 (14) pack years. Approximately one out of five ever smokers had smoked more than 20 pack years. Eighteen percent had completed primary school only, while 22% had university education. Almost half of the study population, twice as many men as women, had been occupationally exposed to dust or gas. Almost 70% of the participants lived in the urban municipality of Bergen.

Prevalence estimates

The prevalence of GOLD defined COPD was 7.0% (table 2). The prevalence was higher in men than in women, and it increased with increasing age and decreasing BMI. COPD was more frequent in ever smokers than in never smokers, and increased in a dose-response manner with pack years. Furthermore, the prevalence was higher in subjects with lower education and in those who had been occupationally exposed to dust or gas. The prevalence of COPD was roughly equal in rural and urban residential areas.

The prevalence of GOLD defined COPD was 27% lower than when COPD was defined before β_2 agonist reversibility testing (table 2). The reduction in the prevalence of COPD after β_2 inhalation was largest in younger age groups and in never smokers. After bronchodilatation, 69 subjects (32% of the pre-bronchodilatation defined prevalent COPD cases) converted from being a COPD case to being a non-case, and 11 subjects (0.5% of the pre-bronchodilatation defined non-cases) converted from being a non-case to being a case. The prevalence of COPD according to GOLD severity stages was 1.8% (95% CI 1.3 to 2.4) mild, 4.2% (95% CI 3.3 to 5.0) moderate, 0.9% (95% CI 0.5 to 1.2) severe, and 0.1% (95% CI 0.0 to 0.3) very severe. This implies that 86% of the COPD cases in our community were mild or moderate.

Changes in pulmonary function after inhalation of adrenergic bronchodilator

Most of the study population maintained a high FEV₁/FVC ratio both before and after reversibility testing. This was true for 90% of the population, while 6.5% had FEV₁/FVC <0.7 both before and after reversibility testing, 3% had a reversible airflow obstruction with a low ratio before bronchodilatation and a high ratio after, and 0.5% had an initial high ratio which decreased after bronchodilatation (table 3). For the 2010 subjects who maintained an FEV₁/FVC ratio of ≥ 0.7 , FVC remained stable from pre- to post-bronchodilator spirometric testing, while FEV₁ increased with a mean of 73 ml. Among subjects with low baseline FEV₁/FVC, all pulmonary function variables increased with post-bronchodilator spirometric testing. In 11 subjects who converted from having an FEV₁/FVC ratio >0.7 to having a ratio <0.7 , FEV₁ decreased slightly (–48 ml on average) while FVC increased considerably (269 ml) after reversibility testing. Reversibility of FEV₁ was highest in the group that went from being a pre-bronchodilator case to a post-bronchodilator non-case (199 ml), with a mean of 122 ml in those who maintained

Table 1 Characteristics of study population by sex, age, body mass index, smoking habits, pack years, occupational exposure and residential area in an adult general Norwegian population, 1996–7

	Women (%)	Men (%)	N (%)
Age (years)			
26–44	434 (39)	496 (45)	930 (42)
45–59	374 (33)	326 (30)	700 (31)
60–74	239 (21)	226 (20)	465 (21)
75–82	82 (7)	58 (5)	140 (6)
Body mass index (kg/m ²)			
<20	80 (7)	32 (3)	112 (5)
20–24.9	543 (49)	426 (38)	969 (43)
25–29.9	338 (30)	530 (48)	868 (39)
>30	162 (14)	117 (11)	279 (13)
Smoking habits			
Never	506 (45)	358 (33)	864 (39)
Ex	262 (23)	357 (32)	619 (28)
Current	361 (32)	391 (35)	752 (33)
Pack years for ever smokers			
1–9	308 (27)	233 (21)	541 (24)
10–19	176 (16)	232 (21)	408 (18)
20+	124 (11)	250 (23)	374 (17)
Educational level			
Primary	215 (19)	189 (17)	404 (18)
Secondary	669 (59)	642 (58)	1311 (59)
University	230 (20)	264 (24)	494 (22)
Occupational exposure to gas or dust			
No	750 (66)	386 (35)	1136 (51)
Yes	350 (31)	699 (63)	1049 (47)
Residential area			
Urban	776 (69)	753 (68)	1529 (68)
Rural	353 (31)	353 (32)	706 (32)
Total	1129 (100)	1106 (100)	2235 (100)

Table 2 Prevalence of COPD (FEV₁/FVC <0.7) defined before and after bronchodilatation in a general adult population in 1996–7 by sex, age, body mass index, smoking habits, pack years, occupational exposure, and residential area

	N	Pre-bronchodilator prevalent cases	Post-bronchodilator prevalent cases	Percentage reduction in prevalence after bronchodilatation relative to before	Estimated post-bronchodilator prevalence (95% CI)
Sex					
Women	1129	65	42	35%	3.7% (2.6 to 4.8)
Men	1106	149	114	23%	10.3% (8.5 to 12.1)
Age (years)					
26–44	930	44	22	50%	2.4% (1.4 to 3.3)
45–59	700	41	29	29%	4.1% (2.7 to 5.6)
60–74	465	88	71	19%	15.3% (12.0 to 18.6)
75–82	140	41	34	17%	24.3% (17.1 to 31.5)
Body mass index (kg/m ²)					
<20	112	16	13	19%	11.6% (5.6 to 17.6)
20–24.9	969	112	75	33%	7.7% (6.1 to 9.4)
25–29.9	868	69	52	25%	6.0% (4.4 to 7.6)
>30	279	17	16	6%	5.7% (3.0 to 8.5)
Smoking habits					
Never smokers	864	46	22	52%	2.5% (1.5 to 3.6)
Ex-smokers	619	75	70	7%	11.3% (8.8 to 13.8)
Current smokers	752	93	64	31%	8.5% (6.5 to 10.5)
Pack years					
1–9	541	39	26	33%	4.8% (3.0 to 6.6)
10–19	408	43	36	16%	8.8% (6.1 to 11.6)
20+	374	79	65	18%	17.4% (13.5 to 21.2)
Educational level					
Primary	404	70	58	17%	14.4% (10.9 to 17.8)
Secondary	1311	113	80	29%	6.1% (4.8 to 7.4)
University	494	27	15	44%	3.0% (1.5 to 4.6)
Occupational exposure to gas or dust					
No	1136	81	55	32%	4.8% (3.6 to 6.1)
Yes	1049	126	94	25%	9.0% (7.2 to 10.7)
Residential area					
Rural	706	64	45	30%	6.4% (4.6 to 8.2)
Urban	1529	150	111	26%	7.3% (6.0 to 8.6)
Total	2235	214	156	27%	7.0% (5.9 to 8.0)

Table 3 One way ANOVA and mean (SD) FEV₁, FVC, and FEV₁/FVC before and after reversibility test by all combinations of pre- and post-bronchodilator defined COPD in a general adult population in 1996–7

	Pre- and post-bronchodilator FEV ₁ /FVC ≥0.7 (N=2010)	Pre- and post-bronchodilator FEV ₁ /FVC <0.7 (N=145)	Pre-bronchodilator FEV ₁ /FVC <0.7 and post-bronchodilator FEV ₁ /FVC ≥0.7 (N=69)	Pre-bronchodilator FEV ₁ /FVC ≥0.7 and post-bronchodilator FEV ₁ /FVC <0.7 (N=11)	p values (one way ANOVA)
Pre-bronchodilator FEV ₁	3.32 (0.89)	2.14 (0.86)	2.83 (1.02)	2.71 (0.77)	<0.001
Pre-bronchodilator FVC	4.16 (1.10)	3.41 (1.21)	4.12 (1.46)	3.64 (1.05)	<0.001
Pre-bronchodilator FEV ₁ /FVC	0.80 (0.05)	0.62 (0.07)	0.68 (0.02)	0.75 (0.08)	<0.001
Post-bronchodilator FEV ₁	3.39 (0.91)	2.26 (0.88)	3.03 (1.06)	2.66 (0.75)	<0.001
Post-bronchodilator FVC	4.15 (1.10)	3.55 (1.19)	4.17 (1.44)	3.91 (1.08)	<0.001
Post-bronchodilator FEV ₁ /FVC	0.82 (0.05)	0.63 (0.07)	0.72 (0.02)	0.68 (0.03)	<0.001

Values are shown as mean (SD).

a low FEV₁/FVC ratio both before and after inhalation of adrenergic bronchodilator (table 3). The Bonferroni multiple pairwise comparison test showed that reversibility and FEV₁/FVC both before and after reversibility testing differed significantly between all four groups (results not shown).

Comparison of subjects with a continuous low FEV₁/FVC ratio and subjects who went from being pre-bronchodilator cases to post-bronchodilator non-cases showed that GOLD defined COPD cases were older than reversible airflow obstruction cases (mean age 63 v 55 years, p<0.001, results not shown), and that significantly more GOLD defined COPD cases reported chronic cough and smoking than those who converted after inhalation of adrenergic bronchodilator.

Risk factors for GOLD defined COPD

There were no significant two way interaction effects from any of the risk factors. The prevalence of COPD increased substantially with age, and more so after bronchodilatation than before (fig 2). Men had 3.3 times higher odds for COPD




Figure 2 Adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for COPD (FEV₁/FVC <0.7) defined before and after bronchodilatation (GOLD defined) in a general adult population in 1996–7 by age, smoking habits, and pack years. Reference categories: 26–44 years, never smokers, 0 pack years. Variables are adjusted for each other as well as for sex, BMI, education, occupational exposure and residential area.




Figure 3 Adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for COPD (FEV₁/FVC <0.7) defined before and after bronchodilatation (GOLD defined) in a general adult population in 1996–7 by sex, body mass index, education, occupational exposure, and residential area. Reference categories: women, BMI 25–29 kg/m², university, no occupational exposure, rural residential area. All variables are adjusted for each other as well as for age and smoking habits.

than women after adjusting for age, BMI, smoking, education, occupational exposure, and residential area (fig 3). An inverse association was observed between COPD and increasing BMI, as the odds ratio for COPD among subjects with BMI <20 kg/m² was 2.4 relative to subjects with BMI 25–29.9 kg/m² (fig 3).

Current smokers had 4.2 times higher odds for COPD than never smokers, and ex-smokers had 3.6 times higher odds for disease than those who had never smoked (fig 2). There was a clear dose-response relationship between smoking and COPD. Although smoking was a significant predictor for COPD both before and after β₂ agonist reversibility testing, the trend was stronger after bronchodilatation than before.

The odds ratio for the prevalence of COPD among subjects with a primary educational level was 2.9 compared with those who had completed university education. Neither

occupational exposure to gas or dust nor residential area was significantly associated with GOLD defined COPD in this study population. The proportion of GOLD defined COPD attributable to smoking was 68% after adjustment for sex, age, BMI, education, occupational exposure to dust or gas, and residential area (results not shown). Less than 6% of COPD in this population could be ascribed to occupational exposure to dust or gas.

Although analyses of interaction effects revealed no significant two way interaction effects from any of the risk factors, separate explorative analyses for men and women were performed to examine whether the risk factor profiles differed (results not shown). The analyses indicated that women may be more susceptible to heavy smoking and that the relationships between low BMI and lower education, on the one hand, and COPD on the other, may be valid primarily for men.

DISCUSSION

The prevalence of GOLD defined COPD was 7% in this general adult population. The reduction in prevalence after bronchodilatation relative to before was 27%. The predictors for COPD remained the same whether disease was defined with or without β_2 agonist reversibility testing, although the strength of the associations varied. Age and smoking were substantially stronger predictors for COPD when defined according to the GOLD criteria than when it was defined without bronchodilatation. The adjusted proportion of GOLD defined COPD attributable to smoking was 68%. Compared with COPD defined before bronchodilatation, fewer young never smokers with reversible airflow limitation would be included as prevalent COPD cases when applying the GOLD post-bronchodilator criteria.

Theoretically, non-response bias could influence prevalence estimates. However, we do not have any reason to suspect important systematic differences between responders and non-responders because of the results from previous studies of the present cohort.^{20, 21} Based on characteristics among the 1985 participants, middle aged subjects in paid employment were over-represented among the responders in 1996–7.²⁰ This indicated a tendency for responders to have higher socioeconomic status than non-responders. However, non-responders and responders in 1996–7 did not differ with regard to the prevalence of morning cough, chronic cough, breathlessness, and wheezing in 1985. A “survivor bias” where only the most healthy of the 1985 participants would be part of the 1996–7 study was therefore found to be unlikely.

The prevalence estimates in our study were based exclusively on spirometric results. Both GOLD and the ATS/ERS guidelines recommend that the presence of respiratory symptoms and a history of exposure to risk factors should be considered in addition to post-bronchodilator spirometric results when diagnosing COPD.^{3, 22} We examined the presence of chronic cough, sputum, dyspnoea, and physician diagnosed COPD, emphysema, bronchitis and asthma in our study population. 73% of the GOLD defined COPD cases were symptomatic and/or had a physician diagnosed respiratory disease. Nearly all the COPD cases identified in our study were mild or moderate cases according to the GOLD severity stages. A recent patient study showed that COPD patients seek medical advice primarily in advanced stages of the disease.²³ Performing routine spirometric tests according to GOLD recommendations could facilitate earlier detection of COPD and those at risk for COPD.

The Estudio Epidemiológico de la EPOC en España (IBERPOC) and the Obstructive Lung Disease in Northern Sweden (OLIN) studies both performed reversibility testing on subjects with initial airflow limitation.^{24, 25} Initial airflow

limitation was defined in the Spanish study as $FEV_1/FVC < 88\%$ of predicted in men and $< 89\%$ of predicted in women, while in the Swedish study it was defined as $FEV_1/FVC < 90\%$ or $FEV_1 < 90\%$ of predicted. For subjects who were not defined as having airflow limitation, spirometric values without bronchodilatation were used in the analyses. In the IBERPOC population with an age range of 40–69 years, the prevalence of ERS defined COPD was 9.1% with smoking, male sex, and age as significant predictors. In the OLIN study three narrow age cohorts (46–47 years, 61–62 years, and 76–77 years) were examined in 1996–7.²⁵ The prevalence of GOLD defined COPD was 14.3%, twice as high as in our study. However, to fulfil the GOLD criteria, reversibility testing should have been performed in all subjects and not just in those with a low initial FEV_1/FVC ratio. Although in most cases the FEV_1/FVC ratio is higher after than before reversibility testing, a considerable number of subjects will have a lower ratio after bronchodilatation than before, as observed in our study. Furthermore, age differences with a mean of 57.3 years in the OLIN study and 49.8 years in the present study could also partly explain the discrepancy between the prevalence estimates. When we included only subjects aged 46–77 years in our analyses, the GOLD defined COPD prevalence was 9.7% (95% CI 7.9 to 11.4) (results not shown).

International comparison of the prevalence of COPD is difficult until more studies provide estimates of COPD according to GOLD and ATS/ERS criteria with appropriate post-bronchodilator spirometric data. The ongoing Burden of Lung Disease (BOLD) initiative²⁶ will facilitate direct comparison of the prevalence of GOLD defined COPD across nations. The BOLD initiative is currently being carried out in study centres in South America, North America, Australia, and Europe.

The GOLD initiative specifies the need for reversibility testing but does not specify in detail a standardised test procedure.² In our study post-bronchodilator spirometric testing was performed 15 minutes after inhalation of 0.3 mg salbutamol from a Turbuhaler. In the OLIN study 0.8 mg salbutamol was inhaled from a Discus, while in the IBERPOC study two inhalations of salbutamol were administered using an inhalation chamber.^{24, 25} Dose, medication, equipment, and time interval from drug inhalation to post-bronchodilator spirometric testing should be included in the guidelines. In addition, comparisons of the prevalence of COPD severity demand identical reference values.

Our study supports previous observations that male sex, old age, smoking, low BMI, and lower education are significant predictors for COPD.^{12, 27, 28} In our study subjects older than 75 years had a 19 times higher risk for COPD than subjects below the age of 45 years. The strength of this age trend may partly be due to the use of the fixed FEV_1/FVC cut off point of 0.7. The age related decline in FEV_1 accelerates in the elderly, and normal ageing of the lung resembles the development of COPD even in subjects without risk factors for COPD.⁷ However, all the 34 prevalent COPD cases older than 75 years in our study reported respiratory symptoms.

Occupational exposure to dust, gases, or fumes is a known risk factor for COPD.²⁹ However, in our study self-reported exposure to airborne dust or gas was not a significant predictor of COPD. A study in 1987–8 from the same area found a positive, but not significant, association between having a job with a high degree of airborne exposure and spirometric airflow limitation.¹⁴ A longitudinal study from the same area also found a positive but not significant association between occupational exposure and COPD.³⁰ A high awareness of the relationship between occupational exposures and chronic lung disease in our community, as well as advanced levels of national safety surveillance

concerning occupational environment, may partly explain our finding.

Becklake and Kauffmann³¹ have stressed the importance of sex-specific analyses in studies of airway disease. Sex-specific analyses revealed mainly the same risk profiles for men and women (results not shown). The analyses nevertheless indicated that women who had smoked more than 20 pack years were more inclined to develop COPD than men who had smoked more than 20 pack years. In addition, the sex-specific results suggest that the relationships between low BMI and lower education, on the one hand, and COPD on the other, may be valid primarily for men. Low BMI was significantly associated with COPD primarily in men. The Tucson study found that being underweight was a predictor for emphysema, while obesity was a predictor for self-reported chronic bronchitis.³² Subjects were categorised as having emphysema or chronic bronchitis if they reported that they had a physician confirmed diagnosis of such disease in a self-administered questionnaire. In our study, self-reported physician diagnosed emphysema was associated with a low BMI in men, and self-reported physician diagnosed bronchitis was associated with a high BMI in women ($p < 0.05$, results not shown). This sex difference regarding the association between BMI and the prevalence of COPD may therefore be due to unequal distribution of COPD phenotypes in men and women. However, whether BMI is a predictor for or a result of COPD is difficult to assess with a cross sectional study design. The predictive value of BMI should be investigated in a population based follow up study.

In conclusion, the GOLD defined prevalence of COPD in a general adult community was 7%. This estimate was reduced by as much as 27% when the GOLD post-bronchodilator criterion was not applied. Predictors of COPD remained the same regardless of β_2 agonist reversibility testing, but smoking and age were stronger predictors after bronchodilatation than before. Two thirds of the prevalent cases could have been prevented if all subjects in this general adult population were non-smokers.

ACKNOWLEDGEMENTS

The authors thank respiratory laboratory technician Lene Svendsen, Centre for Clinical Research for statistical advice and office facilities, and Geir Egil Eide, Tomas Eagan, Sverre Lehmann and Roy Miodini Nilsen for valuable comments.

Authors' affiliations

A Johannessen, E R Omenaas, P S Bakke, A Gulsvik, Institute of Medicine, University of Bergen, Bergen, Norway
P S Bakke, A Gulsvik, Department of Thoracic Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
E R Omenaas, Centre for Clinical Research, Haukeland University Hospital, N-5021 Bergen, Norway

This survey was funded by the Royal Norwegian Council for Scientific and Industrial Research and the Norwegian Research Council.

Competing interests: None declared.

The authors thank Astra Zeneca, Norway for giving them the opportunity to use salbutamol powder by Turbuhaler.

REFERENCES

- 1 **Pauwels RA**, Buist AS, Calverley PM, *et al*. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.

- NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. *Am J Respir Crit Care Med* 2001;**163**:1256–76.
- 2 **Fabbri LM**, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. *Eur Respir J* 2003;**22**:1–2.
- 3 **Celli BR**, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;**23**:932–46.
- 4 **Sterk PJ**. Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV₁. *Eur Respir J* 2004;**23**:497–8.
- 5 **de Marco R**, Accordini S, Cerveri I, *et al*. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. *Thorax* 2004;**59**:120–5.
- 6 **Vestbo J**, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? *Am J Respir Crit Care Med* 2002;**166**:329–32.
- 7 **Hardie JA**, Buist AS, Vollmer WM, *et al*. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. *Eur Respir J* 2002;**20**:1117–22.
- 8 **Celli BR**, Halbert RJ, Isonaka S, *et al*. Population impact of different definitions of airway obstruction. *Eur Respir J* 2003;**22**:268–73.
- 9 **Mannino DM**, Buist AS, Petty TL, *et al*. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. *Thorax* 2003;**58**:388–93.
- 10 **Calverley PM**. The GOLD classification has advanced understanding of COPD. *Am J Respir Crit Care Med* 2004;**170**:211–4.
- 11 **Eagan TM**, Gulsvik A, Eide GE, *et al*. Occupational airborne exposure and the incidence of respiratory symptoms and asthma. *Am J Respir Crit Care Med* 2002;**166**:933–8.
- 12 **Bakke PS**, Hanoa R, Gulsvik A. Educational level and obstructive lung disease given smoking habits and occupational airborne exposure: a Norwegian community study. *Am J Epidemiol* 1995;**141**:1080–8.
- 13 **Nelson SB**, Gardner RM, Crapo RO, *et al*. Performance evaluation of contemporary spirometers. *Chest* 1990;**97**:288–97.
- 14 **Bakke P**, Baste V, Hanoa R, *et al*. Prevalence of obstructive lung disease in a general population: relationship to occupational title and exposure to some airborne agents. *Thorax* 1991;**46**:863–70.
- 15 **American Thoracic Society**. Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med* 1995;**152**:1107–36.
- 16 **Gulsvik A**, Tosteson T, Bakke P, *et al*. Expiratory and inspiratory forced vital capacity and one-second forced volume in asymptomatic never-smokers in Norway. *Clin Physiol* 2001;**21**:648–60.
- 17 **StataCorp**. *Stata Statistical Software: Release 8.0*. College Station, TX: Stata Corporation, 2003.
- 18 **SPSS Inc**. *SPSS Base 12.0 user's guide*. Chicago, IL: Prentice Hall, 2003.
- 19 **Greenland S**, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. *Biometrics* 1993;**49**:865–72.
- 20 **Eagan TM**, Eide GE, Gulsvik A, *et al*. Nonresponse in a community cohort study: predictors and consequences for exposure-disease associations. *J Clin Epidemiol* 2002;**55**:775–81.
- 21 **Bakke P**, Gulsvik A, Lilleng P, *et al*. Postal survey on airborne occupational exposure and respiratory disorders in Norway: causes and consequences of non-response. *J Epidemiol Community Health* 1990;**44**:316–20.
- 22 **Global Initiative for Chronic Obstructive Lung Disease**. *Executive summary update*, 2004. Available at <http://www.goldcopd.com>.
- 23 **Kornmann O**, Beeh KM, Beier J, *et al*. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. *Respiration* 2003;**70**:67–75.
- 24 **Pena VS**, Miravittles M, Gabriel R, *et al*. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. *Chest* 2000;**118**:981–9.
- 25 **Lundback B**, Lindberg A, Lindstrom M, *et al*. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. *Respir Med* 2003;**97**:115–22.
- 26 **Anon**. *Burden of Lung Disease (BOLD) initiative*, 2005. Available at <http://www.kpchr.org/boldcopd>.
- 27 **Prescott E**, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. *Eur Respir J* 1999;**13**:1109–14.
- 28 **Landbo C**, Prescott E, Lange P, *et al*. Prognostic value of nutritional status in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;**160**:1856–61.
- 29 **Blanc PD**, Eisner MD, Trupin L, *et al*. The association between occupational factors and adverse health outcomes in chronic obstructive pulmonary disease. *Occup Environ Med* 2004;**61**:661–7.
- 30 **Johannessen A**, Omenaas E, Bakke P, *et al*. Incidence of GOLD-defined chronic obstructive pulmonary disease in a general adult population. *Int J Tuberc Lung Dis* 2005;**9**:926–32.
- 31 **Becklake MR**, Kauffmann F. Gender differences in airway behaviour over the human life span. *Thorax* 1999;**54**:1119–38.
- 32 **Guerra S**, Sherrill DL, Bobadilla A, *et al*. The relation of body mass index to asthma, chronic bronchitis, and emphysema. *Chest* 2002;**122**:1256–63.